Literature DB >> 25871829

Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac dysfunction.

Kuan-Cheng Chang1, An-Sheng Lee2, Wei-Yu Chen3, Yen-Nien Lin4, Jing-Fang Hsu3, Hua-Chen Chan5, Chia-Ming Chang3, Shih-Sheng Chang4, Chia-Chi Pan3, Tatsuya Sawamura6, Chi-Tzong Chang7, Ming-Jai Su8, Chu-Huang Chen9.   

Abstract

Chronic kidney disease (CKD), an independent risk factor for cardiovascular disease, is associated with abnormal lipoprotein metabolism. We examined whether electronegative low-density lipoprotein (LDL) is mechanistically linked to cardiac dysfunction in patients with early CKD. We compared echocardiographic parameters between patients with stage 2 CKD (n = 88) and normal controls (n = 89) and found that impaired relaxation was more common in CKD patients. Reduction in estimated glomerular filtration rate was an independent predictor of left ventricular relaxation dysfunction. We then examined cardiac function in a rat model of early CKD induced by unilateral nephrectomy (UNx) by analyzing pressure-volume loop data. The time constant of isovolumic pressure decay was longer and the maximal velocity of pressure fall was slower in UNx rats than in controls. When we investigated the mechanisms underlying relaxation dysfunction, we found that LDL from CKD patients and UNx rats was more electronegative than LDL from their respective controls and that LDL from UNx rats induced intracellular calcium overload in H9c2 cardiomyocytes in vitro. Furthermore, chronic administration of electronegative LDL, which signals through lectin-like oxidized LDL receptor-1 (LOX-1), induced relaxation dysfunction in wild-type but not LOX-1(-/-) mice. In in vitro and in vivo experiments, impaired cardiac relaxation was associated with increased calcium transient resulting from nitric oxide (NO)-dependent nitrosylation of SERCA2a due to increases in inducible NO synthase expression and endothelial NO synthase uncoupling. In conclusion, LDL becomes more electronegative in early CKD. This change disrupts SERCA2a-regulated calcium homeostasis, which may be the mechanism underlying cardiorenal syndrome.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiorenal syndrome; Lipoproteins; SERCA2a; Unilateral nephrectomy

Mesh:

Substances:

Year:  2015        PMID: 25871829     DOI: 10.1016/j.yjmcc.2015.03.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis.

Authors:  Chiz-Tzung Chang; Ming-Yi Shen; An-Sean Lee; Chun-Cheng Wang; Wei-Yu Chen; Chia-Ming Chang; Kuan-Cheng Chang; Nicole Stancel; Chu-Huang Chen
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

3.  Electronegative LDL-mediated cardiac electrical remodeling in a rat model of chronic kidney disease.

Authors:  An-Sheng Lee; Wei-Yu Chen; Hua-Chen Chan; Ching-Hu Chung; Hsien-Yu Peng; Chia-Ming Chang; Ming-Jai Su; Chu-Huang Chen; Kuan-Cheng Chang
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 4.  Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia.

Authors:  Márta Sárközy; Zsuzsanna Z A Kovács; Mónika G Kovács; Renáta Gáspár; Gergő Szűcs; László Dux
Journal:  Front Physiol       Date:  2018-11-26       Impact factor: 4.566

5.  Human electronegative LDL induces mitochondrial dysfunction and premature senescence of vascular cells in vivo.

Authors:  Yu-Chen Wang; An-Sheng Lee; Long-Sheng Lu; Liang-Yin Ke; Wei-Yu Chen; Jian-Wen Dong; Jonathan Lu; Zhenping Chen; Chih-Sheng Chu; Hua-Chen Chan; Taha Y Kuzan; Ming-Hsien Tsai; Wen-Li Hsu; Richard A F Dixon; Tatsuya Sawamura; Kuan-Cheng Chang; Chu-Huang Chen
Journal:  Aging Cell       Date:  2018-06-19       Impact factor: 9.304

6.  The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Authors:  Hsiang-Chun Lee; Yi-Lin Shiou; Shih-Jie Jhuo; Chia-Yuan Chang; Po-Len Liu; Wun-Jyun Jhuang; Zen-Kong Dai; Wei-Yu Chen; Yun-Fang Chen; An-Sheng Lee
Journal:  Cardiovasc Diabetol       Date:  2019-04-01       Impact factor: 9.951

7.  Electronegative low density lipoprotein induces renal apoptosis and fibrosis: STRA6 signaling involved.

Authors:  Chao-Hung Chen; Liang-Yin Ke; Hua-Chen Chan; An-Sheng Lee; Kun-Der Lin; Chih-Sheng Chu; Mei-Yueh Lee; Pi-Jung Hsiao; Chin Hsu; Chu-Huang Chen; Shyi-Jang Shin
Journal:  J Lipid Res       Date:  2016-06-02       Impact factor: 5.922

8.  Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels.

Authors:  An-Sheng Lee; Yutao Xi; Chin-Hu Lai; Wei-Yu Chen; Hsien-Yu Peng; Hua-Chen Chan; Chu-Huang Chen; Kuan-Cheng Chang
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

9.  Range of L5 LDL levels in healthy adults and L5's predictive power in patients with hyperlipidemia or coronary artery disease.

Authors:  Chih-Sheng Chu; Hua-Chen Chan; Ming-Hsien Tsai; Nicole Stancel; Hsiang-Chun Lee; Kai-Hung Cheng; Yi-Ching Tung; Hsiu-Chuan Chan; Chung-Ya Wang; Shyi-Jang Shin; Wen-Ter Lai; Chao-Yuh Yang; Richard A Dixon; Chu-Huang Chen; Liang-Yin Ke
Journal:  Sci Rep       Date:  2018-08-08       Impact factor: 4.379

10.  Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis.

Authors:  Chiz-Tzung Chang; Guei-Jane Wang; Chin-Chi Kuo; Ju-Yi Hsieh; An-Sean Lee; Chia-Ming Chang; Chun-Cheng Wang; Ming-Yi Shen; Chiu-Ching Huang; Tatsuya Sawamura; Chao-Yuh Yang; Nicole Stancel; Chu-Huang Chen
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.